This HTML5 document contains 35 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05478/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05478/identifier/drugbank/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05478/identifier/chemspider/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05478
rdf:type
n5:Drug
n5:description
Pradefovir mesilate (previously known as MB-06886, Hepavir B and remofovir mesylate) is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate prodrugs of adefovir. Adefovir (Hepsera) is an acyclic phosphonate analogue of adenine that is used to treat hepatitis B virus. As adefovir is poorly absorbed and associated with a high level of nephrotoxicity, pradefovir mesilate was designed to specifically target the liver and reduce risks to external tissue, especially the kidneys, while improving results of adefovir. Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver. The novel prodrug is highly stable in both plasma and tissues and demonstrated potent preclinical and clinical anti-HBV activity. Pradefovir is undergoing phase II development for the treatment of chronic hepatitis B.
n5:generalReferences
# Reddy KR, Matelich MC, Ugarkar BG, Gomez-Galeno JE, Dare J, Ollis K, Sun Z, Craigo W, Colby TJ, Fujitaki JM, Boyer SH, van Poelje PD, Erion MD: Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B. J Med Chem. 2008 Jan 4;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18173234 # Tillmann HL: Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr Opin Investig Drugs. 2007 Aug;8(8):682-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17668370 # Lin CC, Fang C, Benetton S, Xu GF, Yeh LT: Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16940083 # Lin CC, Xu C, Teng A, Yeh LT, Peterson J: Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. J Clin Pharmacol. 2005 Nov;45(11):1250-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16239358
n5:group
investigational
n5:indication
Investigated for use as a prodrug for Hepsera in treating hepatitis (viral, B).
owl:sameAs
n4:DB05478
dcterms:title
pradefovir mesylate
adms:identifier
n9:7878772 n10:DB05478 n11:9604653
n5:mechanismOfAction
Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver. In this way, it allows for increased Hepsera concentrations selectively in the liver.
n5:toxicity
Good safety profile.
n5:IUPAC-Name
n6:271B44C2-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B44C8-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B44C7-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B44C4-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B44C5-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B44C6-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B44C1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B44CE-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B44CF-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B44C9-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B44CA-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B44CC-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B44CB-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B44CD-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B44D4-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B44D6-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B44D7-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B44D3-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B44D2-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B44D5-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B44C3-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B44D0-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B44D1-363D-11E5-9242-09173F13E4C5